Literature DB >> 11402628

The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus.

G B Kudolo1.   

Abstract

In the first report (Journal of Clinical Pharmacology 2000; 40:647-654), it was shown that ingestion of 120 mg of Ginkgo biloba extract (EGb 761) daily for 3 months by normal glucose-tolerant individuals caused a significant increase in pancreatic beta-cell insulin and C-peptide response, measured as the area under the curve (AUC0-->120) during a 2-hour standard (75 g) oral glucose tolerance test (OGTT). This follow-up study was designed to determine the effect of the same Ginkgo biloba treatment on glucose-stimulated pancreatic beta-cell function in non-insulin-dependent diabetes mellitus (NIDDM) subjects. In diet-controlled subjects (fasting plasma glucose [FPG], 117 +/- 16 mg/dl; fasting plasma insulin [FPI], 29 +/- 8 microU/ml; n = 6), ingestion of Ginkgo biloba produced no significant effect on the insulin AUC0-->120 (193 +/- 53 vs. 182 +/- 58 microU/ml/h, before and after ingesting Ginkgo biloba, respectively). In hyperinsulinemic NIDDM subjects taking oral hypoglycemic medications (n = 6) (FPG 143 +/- 48 mg/dl; FPI 46 +/- 13 microU/ml), ingestion of Ginkgo biloba caused blunted plasma insulin levels from 30 to 120 minutes during the OGTT, leading to a reduction of the insulin AUC0-->120 (199 +/- 33 vs. 147 +/- 58 microU/ml/h, before and after Ginkgo biloba, respectively). The C-peptide levels increased, and so the AUC0-->120 did not parallel the insulin AUC0-->120, creating a dissimilar insulin/C-peptide ratio indicative of an enhanced hepatic extraction of insulin relative to C-peptide. Thus, in pancreatic beta-cells that are already maximally stimulated, ingestion of Ginkgo biloba may cause a reduction in plasma insulin levels. Only in NIDDM subjects with pancreatic exhaustion (FPG 152 +/- 46 mg/dl; FPI 16 +/- 8 microU/ml; n = 8), who also took oral hypoglycemic agents, did Ginkgo biloba ingestion significantly increase pancreatic beta-cell function in response to glucose loading (insulin AUC0-->120 increased from 51 +/- 29 to 98 +/- 20 microU/ml/h, p < 0.0001), paralleled by a C-peptide AUC0-->120 increase from 7.2 +/- 2.8 to 13.7 +/- 6.8 (p < 0.0001). Whether this increase is due to "resuscitation" of previously exhausted islets or increased activity of only the remaining functional islets is unclear. However, not even in this group did increased pancreatic beta-cell activity cause a reduction of blood glucose during the OGTT. It is concluded that ingestion of Ginkgo biloba extract by an NIDDM subject may increase the hepatic metabolic clearance rate of not only insulin but also the hypoglycemic agents. The result is reduced insulin-mediated glucose metabolism and elevated blood glucose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402628     DOI: 10.1177/00912700122010483

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  Reply to Dr. Blumenthal's Letter.

Authors:  George B Kudolo
Journal:  Clin Nutr       Date:  2007-02       Impact factor: 7.324

Review 2.  Antidiabetic Potential of Medicinal Plants and Their Active Components.

Authors:  Bahare Salehi; Athar Ata; Nanjangud V Anil Kumar; Farukh Sharopov; Karina Ramírez-Alarcón; Ana Ruiz-Ortega; Seyed Abdulmajid Ayatollahi; Patrick Valere Tsouh Fokou; Farzad Kobarfard; Zainul Amiruddin Zakaria; Marcello Iriti; Yasaman Taheri; Miquel Martorell; Antoni Sureda; William N Setzer; Alessandra Durazzo; Massimo Lucarini; Antonello Santini; Raffaele Capasso; Elise Adrian Ostrander; Muhammad Iqbal Choudhary; William C Cho; Javad Sharifi-Rad
Journal:  Biomolecules       Date:  2019-09-30

Review 3.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Factors associated with potential medication-herb/natural product interactions in a rural community.

Authors:  Susan J Blalock; Philip J Gregory; Rajul A Patel; Linda L Norton; Leigh F Callahan; Joanne M Jordan
Journal:  Altern Ther Health Med       Date:  2009 Sep-Oct       Impact factor: 1.305

5.  EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes.

Authors:  Soo Lim; Ji Won Yoon; Seon Mee Kang; Sung Hee Choi; Bong Jun Cho; Min Kim; Ho Seon Park; Hyun Ju Cho; Hayley Shin; Young-Bum Kim; Hyo Soo Kim; Hak Chul Jang; Kyong Soo Park
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

6.  Interaction of herbs and glibenclamide: a review.

Authors:  Amita Rai; Cicy Eapen; V G Prasanth
Journal:  ISRN Pharmacol       Date:  2012-07-15

7.  Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rats.

Authors:  Daye Cheng; Bin Liang; Yunhui Li
Journal:  Biomed Res Int       Date:  2012-12-20       Impact factor: 3.411

8.  Ginkgo biloba Extract for Patients with Early Diabetic Nephropathy: A Systematic Review.

Authors:  Lei Zhang; Wei Mao; Xinfeng Guo; Yifan Wu; Chuang Li; Zhaoyu Lu; Guobin Su; Xiaoyan Li; Zhuangzhu Liu; Rong Guo; Xina Jie; Zehuai Wen; Xusheng Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-24       Impact factor: 2.629

9.  Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats.

Authors:  R M Banin; B K S Hirata; I S Andrade; J C S Zemdegs; A P G Clemente; A P S Dornellas; V T Boldarine; D Estadella; K T Albuquerque; L M Oyama; E B Ribeiro; M M Telles
Journal:  Braz J Med Biol Res       Date:  2014-07-25       Impact factor: 2.590

10.  Efficacy and safety of Ginkgo biloba extract as an "add-on" treatment to metformin for patients with metabolic syndrome: a pilot clinical study.

Authors:  Tavga Ahmed Aziz; Saad Abdulrahman Hussain; Taha Othman Mahwi; Zheen Aorahman Ahmed
Journal:  Ther Clin Risk Manag       Date:  2018-07-11       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.